What you should know about ‘breakthrough’ HIV drug

A “significant breakthrough” in HIV prevention could be on the horizon, according to the World Health Organization.

Results of an interim analysis from a Phase 3 clinical trial sponsored by Gilead Sciences, Inc., showed that lenacapavir, a twice-yearly injectable drug, is a highly promising tool for thwarting new HIV infections.

Here, Onyema Ogbuagu, associate professor of medicine (AIDS) and of pharmacology at Yale School of Medicine and the study’s principal investigator, about the trial, named PURPOSE 2, and the future of lenacapavir:

The post What you should know about ‘breakthrough’ HIV drug appeared first on Futurity.

from Futurity https://ift.tt/YJGTKuw